Vericel to Report Fourth-Quarter 2021 Financial Results on February 24, 2022
February 10 2022 - 9:00AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced the following webcast and conference call to discuss its
fourth-quarter 2021 financial results and business highlights.
What: |
|
Vericel Corporation Fourth-Quarter 2021 Earnings Call |
When: |
|
Thursday, February 24, 2022 at
8:30am (EST) |
Where: |
|
http://investors.vcel.com/events-presentations |
How: |
|
The conference call will be
available live in the Investor Relations section of the Vericel
website at http://investors.vcel.com/events-presentations. Please
access the site at least 15 minutes prior to the scheduled start
time in order to download the required audio software if necessary.
Presentation slides for the conference call will be available on
the webcast and in the Investor Relations section of the Vericel
website. |
To participate in the live call by telephone, please call (877)
312-5881 and reference Vericel Corporation’s fourth-quarter 2021
earnings call. If calling from outside the U.S., please use the
international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events-presentations
until February 24, 2023. A replay of the call will also be
available until 11:30am (EST) on February 28, 2022 by calling (855)
859-2056, or from outside the U.S. by calling (404) 537-3406. The
conference ID is 5795764.
About Vericel Corporation
Vericel is a leader in advanced therapies for the sports
medicine and severe burn care markets. The company markets two cell
therapy products in the United States. MACI® (autologous cultured
chondrocytes on porcine collagen membrane) is an autologous
cellularized scaffold product indicated for the repair of
symptomatic, single or multiple full-thickness cartilage defects of
the knee with or without bone involvement in adults. Epicel®
(cultured epidermal autografts) is a permanent skin replacement for
the treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. The
company also holds an exclusive license for North American
commercial rights to NexoBrid®, a registration-stage biological
orphan product for debridement of severe thermal burns. For more
information, please visit the company’s website at
www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2022 Vericel
Corporation. All rights reserved.
Investor Contacts:Eric Burnsir@vcel.com+1 (734)
418-4411
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024